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Purpose. To investigate a frequency of antibody response to SEREX-identified medullary breast carcinoma autoantigens ZRF1
and KRR1 in sera of breast cancer patients taking into account clinical and molecular characteristics of tumors for opening
of new perspectives in creation of minimally invasive immunological tests for cancer diagnostics. Methods. Enzyme-linked
immunosorbent assay and bioinformatics analysis. Results. Increased frequency of antibody response was found in sera of breast
cancer patients toZRF andKRR1 antigens.The antibody response to these antigenswas higher in sera of patientswith invasive ductal
carcinoma than in sera of patients with other histological types of breast tumors.Moreover,more frequent antibody response to ZRF
antigen was found in sera of patients with less aggressive tumors. The sequence analysis of ZRF1 antigen SEREX clones obtained
from cDNA libraries of different tumors demonstrates that they encode different protein isoforms. Conclusion. Tumor-associated
antigens KRR1 and ZRF1 and their cognate autoantibodies could be considered as potential molecular markers of breast cancer
which need to be further investigated.
1. Introduction
Breast cancer is themost common female cancer in the world
with highmortality rate because of high degree ofmalignancy
and rapid proliferation. One of the main problems in breast
cancer diagnostic is that traditional diagnostic methods,
including mammography, ultrasound, magnetic resonance
imaging, and clinical examination, are not sufficiently effec-
tive for tumor detection [1, 2]. For example, mammography
has a high rate of false-positive results and is characterized by
insufficient sensitivity in some groups of women [3–5]. Such
methods as ultrasound and magnetic resonance imaging are
used as additional tools for tumors detection [3]. Moreover,
some tumors can appear in periods between annual mam-
mography screenings being difficult for detection by widely
used screening technologies. So there is a need to search
for new approaches including cancer biomarkers for breast
tumors detection that could provide more effective, simple,
and noninvasive diagnostic tools.
Recent advances in identification and characterization of
tumor-associated antigens (TAAs) indicate that their corre-
spondent autoantibodies are perspective cancer biomarkers,
which have significant advantages compared to other bio-
markers, in particular, the ability to be detected long before
clinical manifestation of the disease and the stability and
availability in blood serum, which open up opportunities to
create minimally invasive cancer diagnostic immune assays
[5, 6]. According to the literature data, the detection rate of
autoantibodies directed against single antigen in the sera of
patients is low and ranges vary in average from 10 to 30%.
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Therefore, the use of panel of TAAs, rather than individual
TAAs, enhances the likelihood of cancer detection. It should
be mentioned that a great number of antigenic panels created
for breast cancer detection consist of well-known breast can-
cer TAAs, in particular p53, c-myc, Her2, Muc1, and survivin
[7]. Most of them are known to be overexpressed in breast
carcinoma tissues and can initiate autoimmune response
[7–9]. Unfortunately, most of the known antigenic panels
have insufficient sensitivity and specificity for breast cancer
diagnostics, and no one of them was approved for use in
clinic. The first commercial panel of antigens “early CDT
lung” was approved by FDA in 2012 to detect autoantibodies
directed to TAAs and assess the risk of lung cancer in the
group of heavy smokers. Therefore, it is important to search
for the new TAAs for creation of more sensitive antigenic
panels, which will be able to discriminate cancer patients
and healthy individuals. Moreover, investigation of antigens
immunogenicity considering clinical and molecular charac-
teristics of tumors including stage, histological type, receptor
status, and grade expands and clarifies their use as biomarkers
for cancer diagnostics.
Identification and characterization of TAAs and their
autoantibodies as molecular markers of humanmalignancies
are the long-standing goal of our Cell Signaling Department.
Up to date, we have identified 81 autoantigens of colon,
thyroid, and breast tumors by SEREX (serological analysis
of recombinant cDNA expression libraries) approach [10–
17].The preliminary phage based allogenic screening showed
that 32 out of 81 SEREX-identified autoantigens had cancer-
related serological profile and reacted only with sera of cancer
patients [11, 15]. Among these immunoreactive autoantigens,
there are 2 proteins; in particular, Zuotin-related factor 1
(ZRF1) and R motif-containing protein 1 (KRR1) (clones KY-
MBC 29-88-1 and KY-MBC 18-53-1) were identified during
the screening of cDNA library from medullary breast carci-
noma. This study aims to confirm cancer-related serological
profile of ZRF1 and KRR1 in large-scale ELISA screening of
their recombinant analogues with sera of breast cancer pa-
tients of different histological types and tumor grades com-
pared with sera of healthy individuals.
2. Methods
2.1. Blood Serum Samples of Patients. In total, 142 patients
with newly diagnosed breast tumors including 22 patients
with nonmalignant fibroadenoma (FA) and 120 patients
with malignant tumors, namely, 87 patients who suffered
from invasive ductal carcinoma (IDC), 23 who had invasive
lobular carcinomas (ILC), and 10 who had medullary breast
carcinomas (MBC), were recruited for this study (Table 1).
56 patients without neoplasm were involved as a control
group.
Serum samples were taken by standard phlebotomywith-
out the use of anticoagulants. Blood samples were kept at
room temperature for 1 hour to form a fibrinogenic clot and
then centrifuged for 15min at 2500×g. Serumwas pulled out,
diluted with glycerol (1 : 1), divided into aliquots, and stored
at −20∘C.
Patient’s tumors have been diagnosed using standard
morphological and clinical criteria in Dnipropetrovsk City
Oncology Center (Dnipropetrovs’k, Ukraine) and the Na-
tional Cancer Institute, the Ministry of Health of Ukraine
[18], Institute of Molecular Biology and Genetics, NASU
(Kyiv, Ukraine), the Clinical Oncological Center (Dnipro-
petrovsk, Ukraine), and National Cancer Institute (Kyiv,
Ukraine), and informed consent was obtained from all pa-
tients.
2.2. Cloning of TAAs cDNA in Bacteria and Purification of
Correspondent Recombinant Proteins. cDNAs of antigens
ZRF1 and KRR1 were amplified from original recombi-
nant ZRF1/pBK-CMV and KRR1/pBK-CMV plasmids and
inserted to pET-28b expression vector by standard cloning
technique using Not1 and Sal1 exonucleases. These cDNAs
which were identified during SEREX screening are not full-
length but they covered the most of coding sequences (CDS)
of cDNAs (Table 2). cDNAs of ZRF1 and KRR1 antigens were
inserted into expression vector pET-28b in the frame with
6His-tag (Table 2) and expressed in E. coli Rosetta (DE3)
pLysS cells. Affine purified recombinant proteins were used
in ELISA screening with sera of breast tumors patients and
healthy donors.
Expression of His-tag fused recombinant proteins was
induced by 1mM IPTG at 37∘C for 4 h in E. coliRosetta (DE3)
pLysS cells transformed by correspondent recombinant plas-
mids. Recombinant proteins were affinity purified using Ni-
NTA-agarose according to manufacturer protocol. Purity of
proteins was analyzed by SDS-PAGE.
2.3. Enzyme-Linked Immunosorbent Assay (ELISA). Detec-
tion of autoantibodies in sera of breast cancer patients was
carried out by ELISA using 96-well plate (Sarstedt, USA).
Recombinant 6His-fused proteins (0,3𝜇g) were added to the
wells in phosphate buffer (PBS), pH 7,4 (3,2mM Na
2
HPO
4
;
0,5mM KH
2
PO
4
; 1,3mM KCl; 135mM NaCl); sorption
was carried out during the night at +4∘C. The plates were
washedwith 0.1% PBS-T (phosphate buffer with 0.1%Tween),
followed by blocking of binding sites with 0.1% PBS-T and
5% casein hydrolyzate (USB, USA) for 2 h at 37∘C. Serum
samples (at a dilution of 1 : 100 in phosphate buffer with 0.5%
casein hydrolyzate) were dispensed in duplicate of 100𝜇L per
well and incubated for 90min at 37∘C. After four washings,
antibodies conjugated to horseradish peroxidase (Jackson
ImmunoResearch, USA) and directed against Fc-fragment of
human IgG were added upon dilution of 1 : 104 in phosphate
buffer with 1% casein hydrolyzate and incubated for 1 h at
37∘C. After washing, 100𝜇L of chromogenic substrate ABTS
(2,2󸀠-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid))
(Sigma, USA) was added per well and incubated for 30min
at 37∘C. Optical density (OD) was determined at 𝐴
410
using
a spectrophotometer BioTek (USA).
2.4. Statistical Analysis. Primary data systematization and
analysis were performed using Excel software (Microsoft
Office, 2007). The antibody test (ELISA) was positive if
optical density (OD) of serum samples exceeded the received
threshold. The threshold of the test was adopted as the mean
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Table 1: Characteristics of tumor patients and healthy donors.
Characteristics Samples description
(1) Group of healthy donors
Number of healthy women 56
Age at diagnosis, years (range, mean ± SD) 17–60, 40,11 ± 12,20
The number of healthy donors 45 years old or older 21
The number of healthy donors younger than 45 years 35
(2) Group of patients with benign breast tumors
Number of fibroadenoma patients 22
Age at diagnosis, years (range, mean ± SD) 24–63, 30 ± 9,54
The number of fibroadenoma patients 45 years old or older 2
The number of fibroadenoma patients younger than 45 years 20
(3) Group of cancer patients
Number of patients 120
Age at diagnosis, years (range, mean ± SD) 36–83, 59.55 ± 11,63
The number of cancer patients 45 years old or older 112
The number of cancer patients younger than 45 years 8
Tumor type
Invasive ductal breast carcinoma 87
Invasive lobular breast carcinoma 23
Medullary breast cancer 10
Tumor grade (% from general) 83
Grade 1: 4,82
Grade 2: 37,35
Grade 3: 57,83
ER-status (%) 52
Positive 71,1
Negative 28,9
PR-status (%) 52
Positive 30,8
Negative 69,2
HER-2/neu status (%) 52
Positive 30,8
Negative 69,2
Lymphoid nodes status (% of positive) 28,8
SD: standard deviation.
Table 2: Antigens included in serological screening.
Antigen Full name cDNA referencesequence (NCBI db)
cDNA-fragment according
to correspondent NCBI
reference sequence, bp
Vector
MW of recombinant
protein, kDa (with
6His-tag)
ZRF1 Zuotin-related factor 1 NM 014377.1CDS 252⋅ ⋅ ⋅ 2117 942–2117 pET-28b (6His-tag) 47,52
KRR1 R motif-containing protein 1 NM 007043.6CDS 42⋅ ⋅ ⋅ 1187 42–1161 pET-28b (6His-tag) 46,31
plus 2 standard deviations of the OD values of all healthy
donors’ samples. To determine whether the frequency of
autoantibodies to each of two TAAs was significantly higher
in sera of breast cancer patients comparedwith sera of healthy
donors, data were analyzed using the chi-squared test and 𝑡-
test. In view of great age variety in group of healthy donors
and groups of breast cancer and fibroadenoma patients, the
comparisons were performed between age-matched groups.
For groups that include 5 or less members, statistical analysis
was not executed.
2.5. Bioinformatics Analysis. Bioinformatic analysis of SE-
REX clones sequences was performed using bioinformatics
tools provided by NCBI (http://www.ncbi.nlm.nih.gov/),
GeneCards (http://www.genecards.org/), SEREX (http://www
.ludwig-sun5.unil.ch/CancerImmunomeDB/), andCLUSTAL
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Table 3: Frequency of antibody response towardKRR1 and ZRF1 antigens in the sera of patients of different histological types of breast tumors
in view of age∗.
Antigen
The number of positive sera∗∗, n (%)
HD over 45
(𝑛 = 21)
HD under 45
(𝑛 = 35)
BC over 45
(𝑛 = 112)
MBC over 45
(𝑛 = 7)
IDC over 45
(𝑛 = 82)
ILC over 45
(𝑛 = 23)
FA under 45
(𝑛 = 20)
ZRF1 1 (4,76) 1 (2.86) 28 (25,00)† 1 (14,29) 22 (26,83)† 5 (21,74) 2 (10,00)
Mean ± SD 0,1513 ± 0,057 0,1446 ± 0,049 0,2242 ± 0,132 0,20534 ± 0,061 0,2383 ± 0,144 0,18 ± 0,084 0,1706 ± 0,094
KRR1 0 (0) 2 (5,71) 23 (20,54)† 1 (14,29) 21 (25,61)† 1 (7,14) 0 (0)
Mean ± SD 0,2288 ± 0,080 0,2403 ± 0,060 0,3246 + 0,080 0,2843 ± 0,072 0,3430 ± 0,077 0,2712 ± 0,068 0,1884 ± 0,054
Notes: ∗statistical analysis of frequency of antibody response was calculated between BC patients and healthy individuals cohorts over 45 years old and between
FA and healthy individuals cohorts under 45 years old; ∗∗threshold: the mean plus 2 SD in the group of healthy donors; †Statistically significant difference
compared to healthy donors’ sera (𝑃 < 0.05). HD: healthy donors; BC: breast cancer (IDC + ILC + MBC); MBC: medullary breast carcinoma; IDC: invasive
ductal carcinoma; ILC: invasive lobular carcinoma; FA: fibroadenoma.
W (1.83) (http://embnet.vital-it.ch/software/ClustalW.html)
resources.
3. Results
3.1. Cloning of cDNAs of KRR1 and ZRF1 Antigens, Expression,
and Purification of Correspondent Recombinant Proteins. In
this investigation, our attention was focused on two potential
tumor-associated antigens, namely, Zuotin-related factor 1
(ZRF1) and R motif-containing protein 1 (KRR1), previously
identified by SEREX analysis of medullary breast carcinoma
cDNA library [12, 15]. These antigens had tumor-associated
serological profile of autoantibodies according to the data of
preliminary phage based allogeneic screening with sera of
medullary breast carcinoma patients [12]. Recombinant plas-
mids ZRF1/pBK-CMV and KRR1/pBK-CMV were obtained
by “in vivo excision” procedure of cDNA of phage 𝜆 positive
clones of MBC cDNA library during previous investigation
[12, 15].
3.2. Analysis of Antibody Response to KRR1 and ZRF1 Recom-
binant Proteins in the Sera of Breast Tumors Patients and
Healthy Donors. Recombinant proteins were analyzed in the
allogenic screening using sera of patients with different his-
tological types and tumor grades compared with sera of
healthy individuals. Since the most of breast patients were
over 45 years of age while the most of the fibroadenoma
patients and healthy individuals were under 45 years of
age, we performed comparative analysis of serum reactivity
in corresponding age-matched groups. Table 3 presents the
results of large-scale allogeneic screening of two investigated
antigens. Increased frequency of autoantibody response to
ZRF1 and KRR1 antigens was detected in 25.00% and 20.54%
of breast cancer patients’ sera, respectively (Table 3).
Analysis of antibody response frequency toward KRR1
and ZRF antigens in the sera of breast cancer patients taking
into account histological type of tumors showed a statistically
significant antibody response only in sera of patients with
invasive ductal carcinomas. For ZRF1, significant reactivity
also was shown in sera of patients with G1 and G2 tumors
(Table 4).
We found no significant difference of frequency of
antibody response in sera of breast cancer patients taking
Table 4: Frequency of antibody response toward KRR1 and ZRF1
antigens in the sera of breast cancer patients of different tumor
grade.
Tumor grade (n: the
number of positive sera∗)
Antigens
ZRF1 KRR1
G1 + G2 (𝑛 = 35) 42,86 (15)† 20 (7)
G3 (𝑛 = 48) 18,75 (9) 18,75 (9)
G1: grade 1 tumor,G2: grade 2 tumor, andG3: grade 3 tumor;n: the number of
positive sera; ∗threshold: the mean plus 2 SD in the group of healthy donors.
†Statistically significant difference compared to G3 tumor grade (𝑃 < 0.05).
into account tumor’s receptor and lymphoid nodes sta-
tus.
As it was mentioned above, ZRF1 (also known as
DNAJC2, MPP11) was described as SEREX-antigen in differ-
ent malignancies [19–22]. Totally, 4 SEREX clones NY-SCLC-
6, NY-BR-13, NGO-St-58 5󸀠, and UL-CML-1 have been iden-
tified by screening of cDNA libraries from lung, breast, and
stomach cancers and leukemia correspondingly (Table 5).
Analysis of antibody response in sera of cancer patients
toward the protein products of these clones according to
literature data and our own results showed contradictory
outcomes (Table 5). These data prompted us to perform
analysis of available sequence of SEREX clones which encode
ZRF1 (DNAJC2, MPP11) antigen.
3.3. Analysis of Sequences of SEREX Clones Identified from
Different Tumors, Which Encode ZRF1 Antigen. Today there
are three available cDNA sequences of ZRF1 SEREX clones:
NGO-St-58, NY-BR-13, and KY-MBC 29-88-1.The NY-BR-13
clone was identified by Matthew Scanlan (Ludwig Institute
for Cancer Research, NY, USA) by screening of breast
cancer cDNA library and NGO-St-58 5󸀠 clone was identified
by Yuichi Obata (Aichi Cancer Center, Tokyo, Japan) by
screening of stomach cancer cDNA library (Table 5).
Comparative analysis of sequences of these clones re-
vealed 159 bp length insertions in the sequences of clones
NGO-St-58 and KY-MBC 29-88-1 that was absent in the
sequence of NY-BR-13 clone (Figure 1). BLAST analysis of
cDNA sequences of NY-BR-13, NGO-St-58, and KY-MBC
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Table 5: SEREX clones which encode ZRF1 (DNAJC2, MPP11) antigen.
Clone name Source
Frequency of antibody response in
cancer patients sera versus healthy
donors sera
Publication
NY-SCLC-6
NCI-H740 and
SK-LC-13 cell
lines
N/A Gu¨re et al., PNAS, 2000; 97: 4198–4203 [19]
NY-BR-13 Breast cancer 3/10 BC versus 3/12 HD Scanlan et al., Cancer Immun 2001: 4–21 [20].(Ludwig-sun5.unil.ch/CancerImmunomeDB/)
NGO-St-58, 5 Stomach cancer 4/13 SC versus 3/16 HD Obata et al. (Ludwig-sun5.unil.ch/CancerImmunomeDB/)[21]
UL-CML-1
K562 cell line
from CML
patient
7/19 AML, 6/16 CML, 4/10 RCC, 3/6
MM, 3/12 BC, 3/10 OC versus 0/20 HD Greiner et al., Int. J. Cancer 2003; 106: 224–231 [22].
KY-MBC
29-88-1 Breast cancer
33/120 BC (including 1/10 MBC, 27/87
IDC, 5/23 ILC), 3/22 FA versus 2/50 HD Present paper
BC: breast cancer patients; HD: healthy donors; SC: stomach cancer; RCC: renal cell carcinoma; MM: metastatic melanoma; AML: acute myeloid leukemia;
CML: chronic myeloid leukemia; OC: ovarian carcinoma.
KY-MBC-29-88-1 GCTAAGGAGAAAGAAGAGGAGGAAGTCAGACAGCAAGCATTGCTGGCAAAGAAGGAAAAA
NGO-ST-58 GCTAAGGAGAAAGAAGAGGAGGAAGTCAGACAGCAAGCATTGCTGGCAAAGAAGGAAAAA
NY-BR-13 GCTAAGGAGAAAGAAGAGGAGGAAGTCAGACAGCAAGCATTGCTGGCAAAGAAGGAAAAA
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
KY-MBC-29-88-1 GATATCCAGAAAAAAGCCATTAAGAAGGAAAGGCAAAAACTTCGAAACTCATGCAAGACC
NGO-ST-58 GATATCCAGAAAAAAGCCATTAAGAAGGAAAGGCAAAAATTTCGAAACTCATGCAAGACC
NY-BR-13 GATATCCAGAAAAAAGCCATTAAGAAGGAAAGGCAAAAACTTCGAAACTCATGCAAGA--
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗ ∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
KY-MBC-29-88-1 TGGAATCATTTTTCTGATAATGAGGCAGAGCGGGTTAAAATGATGGAAGAAGTGGAAAAA
NGO-ST-58 TGGAATCATTTTTCTGATAATGAGGCAGAGCGGGTTAAAATGATGGAAGAAGTGGAAAAA
NY-BR-13 ------------------------------------------------------------
KY-MBC-29-88-1 CTTTGTGATCGGCTTGAACTGGCAAGCTTACAGTGCTTGAATGAAACACTCACATCATGC
NGO-ST-58 CTTTGTGATCGGCTTGAACTGGCAAGCTTACAGTGCTTGAATGAAACACTCACATCATGC
NY-BR-13 ------------------------------------------------------------
KY-MBC-29-88-1 ACAAAAGAAGTAGGAAAGGCTGCTTTGGAAAAACAGATAGAAGAAATAAATGAGCAAATC
NGO-ST-58 ACAAAAGAAGTNGGAAAGGCTGCTTTGGAAAAACAGATAGAAGAAATAAATGAGCAAATC
NY-BR-13 -------------------------------------TAGAAGAAATAAATGAGCAAATC
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗ ∗∗ ∗
KY-MBC-29-88-1 AGAAAAGAGAAAGAGGAAGCTGAGGCTCGTATGCGACAAGCATCTAAGAACACAGAGAAA
NGO-ST-58 AGAAAAGAGAAAGAGGAAGCTGAGGCTCGTATGCGACAAGCATCTAAGAACACAGAGAAA
NY-BR-13 AGAAAAGAGAAAGAGGAAGCTGAGGCTCGTATGCGACAAGCATCTAAGAACACAGAGAAA
Figure 1: Part of multiple alignment of KY-MBC 29-88-1, NGO-St-58, and NY-BR-13 clones sequences by CLUSTALW (1.83) analysis.
29-88-1 clones showed that sequences of clones NGO-St-
58 and KY-MBC 29-88-1 correspond to the longer mRNA
transcript 1 of DNAJC2 gene (Ref. sec. NM 014377.1), while
full-length sequence of NY-BR-13 clone (reference sequence
X98260) corresponds to the shorter mRNA transcript 2 of
DNAJC2 gene (Ref. sec. NM 001129887.1) that differs by
159 bp (Table 6). Unfortunately, we could not analyze se-
quences of UL-CML-1 and NY-SCLC-6 clones because they
were not found [19, 22].
Obtained data indicate that at least three SEREX clones
KY-MBC 29-88-1, NGO-St-58, and NY-BR-13 correspond to
different mRNA transcripts of DNAJC2 gene, which encode
in turn two different protein isoforms (Table 6).
4. Discussion
Tumor-associated antigens and their correspondent autoan-
tibodies are promising molecular markers for diagnostics
and therapy of human malignancy. Today more than 2000
TAAs have been identified by different approaches includ-
ing SEREX, SEPRA, phage display, microarray, and other
high throughput technologies [14, 23]. Previously, we have
described 81 autoantigens identified from breast, colon, and
thyroid cancers by SEREX approach [10, 12, 13, 15, 16].
Original modification of SEREX technique for the generation
of medullary breast carcinoma cDNA expression library
depleted from IgG genes has been developed [12]. As a
result, MBC cDNA library suitable for serological screening
was created and 41 MBC-derived autoantigens have been
identified [12]. Preliminary phage based allogenic screen-
ing revealed that 18 of them had exhibited cancer-related
autoantibody profile and reacted only with sera of medullary
breast carcinoma patients but not with sera of healthy donors
[12, 15]. Here, we studied immunogenicity of 2 out of 18
MBC antigens, namely, ZRF1 and KRR1, in sera of patients
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with breast tumors of different histological types and grades
compared with sera of age-matched healthy donors using
large-scale allogeneic screening performed by ELISA.
Zuotin-related factor 1 (ZRF1) and R motif-containing
protein 1 (KRR1) have a multifunctional role in different cell
processes including malignant transformation. KRR1 is a fac-
tor involved in a process of ribosomal assembly and essential
for cell viability [24]. Some data demonstrate that KRR1 is
highly expressed in dividing cells; moreover, its expression
ceases almost completely, when cells enter the stationary
phase. In vivo depletion of KRR1 leads to vigorous reduc-
tion of 40S ribosomal subunits due to defective 18S rRNA
synthesis [24]. There is a little data about KRR1 function in
tumors. It was suggested only that KRR1 is associated with
metastasis in malignant fibrous histiocytoma [23]. During
this study, we identified for the first time increased frequency
of antibody response toward KRR1 antigen in sera of breast
cancer patients and in sera of patients with invasive ductal
breast carcinoma compared with sera of healthy women.
Zuotin-related factor 1 (ZRF1), that has several names
including DNAJC2 (Hsp40); ZUO1; MPP11; MPHOSPH11
and is encoded by DNAJC2 gene, is a member of the M-
phase phosphoprotein (MPP) family, which acts as both a
chaperone in the cytosol [25] and a chromatin regulator in
the nucleus [26].The chromosomal aberrations involving this
gene are associated with primary head and neck squamous
cell carcinomas (HNSCC) [27]. A tumor-specific high level
of MPP11 expression in HNSCC was shown [27]. Cluster
analysis showed that gene, which is EST, ismoderately similar
to ZFR1, displayed differential expression in lymph node
positive and negative gastric tumors [28]. The mutation in
the human Mpp11 J protein (ZRF1) which leads to loss of
function of this protein has been described [25]. Some
authors concluded that ZRF1 involved in regulation of cellular
proliferation and senescence and alterations in ZRF1 may
contribute to tumorigenesis [29]. Analysis performed during
this study showed increased frequency of antibody response
toward ZRF1 antigen in sera of patients with invasive ductal
carcinomas. Greiner et al. [22] also demonstrated significant
antibody response toward MPP11 in the sera of breast cancer
patients but not in sera of healthy volunteers. These data
contradict the data of Obata et al. [21] and Scanlan et al.
[20] who both failed to show increased immunogenicity of
ZRF1 antigen in sera of stomach and breast cancer patients
correspondingly compared with sera of healthy women. This
concordance was explained by Greiner in part by different
cDNAs lengths of SEREX clones thatmight result in a various
conformation of the gene’s protein products and subsequently
in a different epitope presentation to IgG antibodies [22].
We performed analysis of SEREX clones (NY-BR-13,
NGO-St-58, and KY-MBC 29-88-1) sequences coding ZRF1
and revealed 159 bp lengths insert in the sequences of clones
NGO-St-58 and KY-MBC 29-88-1. BLAST analysis indicated
that sequences of clones NGO-St-58 and KY-MBC 29-88-1
correspond to longer transcript variant 1 of DNAJC2 gene,
while sequence of NY-BR-13 clone corresponds to shorter
transcript variant 2 ofDNAJC2 gene.Thus, these data allowed
us to suppose that NGO-St-58, KY-MBC 29-88-1, and NY-
BR-13 SEREX clones correspond to 2 alternatively spliced
mRNA isoforms of DNAJC2 gene, that encode two different
protein isoforms. This observation, in part, can explain
differences in allogenic screening results of these SEREX
clones performed by different researchers. Due to previous
literature data and data obtained in this study, we suggest that
different protein isoforms and/or mutant forms of DNAJC2
could be differently expressed in various tumors and may
differ in immunogenicity. In addition, increased frequency
of antibody response in sera of patients with less aggressive
tumors (G1 and G2) shown during this study allowed us to
suppose that autoantibodies towardZFR1 antigenmay appear
at the initial steps of breast cancer malignancy and represent
potential markers for early cancer diagnostics.
So, analysis of antibody response in sera of breast cancer
patients with tumors of different clinical and molecular
characteristics showed that KRR1 and ZRF1 antigens and
autoantibodies thereto are potential breast tumor mark-
ers, which could be important for creation of new anti-
genic/autoantibody signatures for breast tumor detection
including early breast cancer diagnostics and/or for improv-
ing already existing ones. Comparative analysis of ZRF1
SEREX clones showed that they code different protein iso-
forms of DNAJC2 gene in different tumors and cell lines.
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